12 results on '"Nobuhiro Takeshita"'
Search Results
2. Hepatic resection in 485 R0 pT2 and pT3 cases of advanced carcinoma of the gallbladder: results of a Japanese Society of Biliary Surgery survey—a multicenter study
- Author
-
Yoshihito Kodera, Tatsuya Yoshikawa, Takehiro Ota, Ryouta Higuchi, Nobuhiro Takeshita, Masakazu Yamamoto, Mie Hamano, Ken Takasaki, and Tatsuo Araida
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Gastroenterology ,Postoperative Complications ,Japan ,Surveys and Questionnaires ,Internal medicine ,medicine ,Carcinoma ,Hepatectomy ,Humans ,Practice Patterns, Physicians' ,Gallbladder cancer ,Survival rate ,Aged ,Neoplasm Staging ,Retrospective Studies ,Hepatology ,business.industry ,Gallbladder ,Hepatoduodenal ligament ,Middle Aged ,medicine.disease ,Surgery ,Survival Rate ,Treatment Outcome ,medicine.anatomical_structure ,Female ,Gallbladder Neoplasms ,business ,Abdominal surgery - Abstract
We conducted this study to evaluate the optimal hepatic resection for pT2 and pT3 advanced carcinoma of the gallbladder without invasion of the hepatoduodenal ligament. We conducted a questionnaire survey regarding 4,243 cases of carcinoma of the gallbladder treated during the recent 10-year period at 112 institutions belonging to the Japanese Society of Biliary Surgery. The questionnaires included questions on preoperative-diagnosis, complications, treatment, and surgical treatment, procedures of resection, surgical result, path histological findings, mode, and site of recurrence, additional post-operative treatment. They included 293 pT2 and 192 pT3 R0 cases, which were negative for hepatoduodenal ligament invasion, and the cumulative survival rates and sites of postoperative recurrence in the form of liver metastasis, were retrospectively analyzed in these 485 cases. There were no significant differences in survival rate or recurrence rates in the form of liver metastasis between the groups that underwent resection of the gallbladder bed, the group that underwent segmentectomy 4a+5, and the group that underwent hepatectomy in patients with of both pT2 or pT3 gallbladder cancers. Our results also did not show that liver metastasis to segment 4a5 alone was particularly common. For gallbladder cancer, neither with hepatoduodenal ligament invasion nor hepatic invasion, resection of the gallbladder bed is more preferable for surgical hepatic procedure. For gallbladder cancer that invades any hepatic sites, a hepatic surgical procedure that could eliminate surgical margins would be desirable.
- Published
- 2009
- Full Text
- View/download PDF
3. Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma
- Author
-
Satoshi Katagiri, Kenji Yoshitoshi, Shunichi Ariizumi, Nobuhiro Takeshita, Atsushi Aruga, Masakazu Yamamoto, Ken Takasaki, Yutaka Takahashi, Koichi Shimizu, and Yoshihito Kotera
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adoptive cell transfer ,Pathology ,Carcinoma, Hepatocellular ,Non-Randomized Controlled Trials as Topic ,T cell ,medicine.medical_treatment ,T-Lymphocytes ,Immunology ,Gastroenterology ,Cancer Vaccines ,Young Adult ,Recurrence ,Internal medicine ,medicine ,Adjuvant therapy ,Immunology and Allergy ,Humans ,neoplasms ,Aged ,Pharmacology ,Aged, 80 and over ,Postoperative Care ,business.industry ,Standard treatment ,Liver Neoplasms ,Dendritic cell ,Immunotherapy ,Dendritic Cells ,Middle Aged ,medicine.disease ,Adoptive Transfer ,digestive system diseases ,medicine.anatomical_structure ,Treatment Outcome ,Hepatocellular carcinoma ,Female ,Cancer vaccine ,business ,Research Paper - Abstract
The recurrence rate after surgery in patients with hepatocellular carcinoma (HCC) is very high, while prognosis is quite poor. However, there is no standard treatment to prevent recurrence of HCC after a curative operation. In this study, we investigated the clinical utilization of an autologous tumor lysate-pulsed dendritic cell vaccine plus ex vivo activated T cell transfer (ATVAC) in an adjuvant setting for postoperative HCC as a non-randomized controlled trial. Ninety-four patients with invasive HCC received informed consent information regarding the study, and 42 opted to have the ATVAC after surgery. Their recurrence-free survival (RFS) and overall survival (OS) were measured after 5 years and compared with those of 52 patients who selected to have the curative operation alone. The median RFS and OS were 24.5 months and 97.7 months in the patients receiving adjuvant ATVAC and 12.6 months and 41.0 months in the group receiving surgery alone (P = 0.011 and 0.029). In the treated group, patients with positive delayed-type hypersensitivity (DTH) had a better prognosis (RFS P = 0.019, OS P = 0.025). No adverse events of grade 3 or more were observed. A postoperative dendritic cell vaccine plus activated T cell transfer would be a feasible and effective treatment for preventing recurrence in HCC patients and achieving long-term survival especially in DTH positive patients.
- Published
- 2014
4. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer
- Author
-
Norimasa Matsushita, Yoshihito Kotera, Atsushi Aruga, Masakazu Yamamoto, Ryuji Okuyama, Takehiro Ohta, Kazuyoshi Takeda, and Nobuhiro Takeshita
- Subjects
Oncology ,Male ,Cancer Research ,medicine.medical_specialty ,Time Factors ,T-Lymphocytes ,HLA-A24 Antigen ,Enzyme-Linked Immunosorbent Assay ,Cancer Vaccines ,Disease-Free Survival ,Epitopes ,Interferon-gamma ,Immune system ,Antigen ,Antigens, Neoplasm ,Internal medicine ,Lymphopenia ,Injection site reaction ,Testis ,Medicine ,Humans ,Adverse effect ,Aged ,business.industry ,Vaccination ,Common Terminology Criteria for Adverse Events ,Middle Aged ,medicine.disease ,Flow Cytometry ,Prognosis ,Clinical trial ,Biliary Tract Neoplasms ,Treatment Outcome ,Immunology ,Vaccines, Subunit ,Cancer/testis antigens ,Female ,business ,T-Lymphocytes, Cytotoxic - Abstract
Purpose: The prognosis of patients with advanced biliary tract cancer (BTC) is extremely poor and there are only a few standard treatments. We conducted a phase I trial to investigate the safety, immune response, and antitumor effect of vaccination with four peptides derived from cancer-testis antigens, with a focus on their fluctuations during long-term vaccination until the disease had progressed. Experimental Design: Nine patients with advanced BTC who had unresectable tumors and were refractory to standard chemotherapy were enrolled. HLA-A*2402–restricted epitope peptides, lymphocyte antigen 6 complex locus K, TTK protein kinase, insulin-like growth factor-II mRNA-binding protein 3, and DEP domain containing 1 were vaccinated subcutaneously once a week at doses of 0.5, 1, or 2 mg and continued until disease progression. The adverse events were assessed by Common Terminology Criteria for Adverse Events and the immune response was monitored by an enzyme-linked immunospot assay or by flow cytometry. The clinical effects observed were tumor response, progression-free survival (PFS), and overall survival (OS). Results: Four-peptide vaccination was well tolerated. No grade 3 or 4 adverse events were observed. Peptide-specific T-cell immune responses were observed in seven of nine patients and clinical responses were observed in six of nine patients. The median PFS and OS were 156 and 380 days. The injection site reaction and CTL induction seemed to be prognostic factors of both PFS and OS. Conclusions: Four-peptide vaccination was well tolerated and seemed to provide some clinical benefit to some patients. These immunologic and clinical responses were maintained over the long term through continuous vaccinations. Clin Cancer Res; 19(8); 2224–31. ©2013 AACR.
- Published
- 2013
5. Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma
- Author
-
Ken Takasaki, Koichi Shimizu, Nobuhiro Takeshita, Yoshihito Kotera, Masakazu Yamamoto, and Atsushi Aruga
- Subjects
Oncology ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,T-Lymphocytes ,Lymphocyte Activation ,Cancer Vaccines ,Cholangiocarcinoma ,Surgical oncology ,Internal medicine ,medicine ,Adjuvant therapy ,Humans ,Prospective Studies ,Prospective cohort study ,Intrahepatic Cholangiocarcinoma ,Aged ,Postoperative Care ,Hepatology ,business.industry ,Standard treatment ,Liver Neoplasms ,Immunotherapy ,Dendritic Cells ,Middle Aged ,Adoptive Transfer ,Bile Ducts, Intrahepatic ,Treatment Outcome ,Bile Duct Neoplasms ,Surgery ,Female ,Cancer vaccine ,business ,Adjuvant - Abstract
The prognosis of patients with intrahepatic cholangiocarcinoma (ICC) is extremely poor and the recurrence rate after curative operation is very high. There is no standard treatment to prevent recurrence of ICC. In this study, we investigated the clinical utilization of a dendritic cell vaccine plus activated T-cell transfer in an adjuvant setting for postoperative ICC. 36 patients with ICC were vaccinated at least 3 times with autologous tumor lysate pulsed dendritic cells plus ex-vivo activated T-cell transfer. The 5-year progression-free survival (PFS) and overall survival (OS) were measured and compared with those of 26 patients who received the curative operation alone as a concurrent control. The registration number was UMIN000005820. The median PFS and OS were 18.3 and 31.9 months in the patients receiving adjuvant immunotherapy and 7.7 and 17.4 months in the group receiving surgery alone (p = 0.005 and 0.022, respectively). In the treated group, patients whose skin reactions were 3 cm or more at the vaccine site showed dramatically better prognosis (PFS p
- Published
- 2011
6. Forty-year experience with flow-diversion surgery for patients with congenital choledochal cysts with pancreaticobiliary maljunction at a single institution
- Author
-
Masakazu Yamamoto, Takehiro Ota, and Nobuhiro Takeshita
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Cholangiocarcinoma ,Young Adult ,Pancreatectomy ,Postoperative Complications ,Bile Ducts, Extrahepatic ,Congenital Choledochal Cyst ,Cause of Death ,Medicine ,Humans ,Choledochal cysts ,Single institution ,Child ,Aged ,Retrospective Studies ,Flow diversion ,business.industry ,Liver Cirrhosis, Biliary ,General surgery ,Pancreatic Ducts ,Middle Aged ,medicine.disease ,Biliopancreatic Diversion ,Surgery ,Survival Rate ,Bile Ducts, Intrahepatic ,Pancreaticobiliary maljunction ,Bile Duct Neoplasms ,Child, Preschool ,Choledochal Cyst ,Pancreatic juice ,Pancreatitis ,Female ,business ,Follow-Up Studies - Abstract
Congenital choledochal cyst with pancreaticobiliary maljunction (PBM) is known as a high-risk factor for various complications such as cholangitis, pancreatitis, and carcinogenesis of the biliary system by mutual refluxes of bile and pancreatic juice. Furthermore, it is not rare to suffer from postoperative complications if the wrong operative procedure is chosen. Therefore, we sought to review the relationship between operative procedure for types I and IV-A (Todani's classification) congenital choledochal cyst with PBM, and long-term treatment outcome.A retrospective review was carried out of 144 patients who underwent flow diversion surgery in our institution during the 40-year period from 1968 to 2008 and who did not have a coexisting malignant tumor at the time of surgery.Of these 144 patients, 137 underwent complete cyst excision and 7 underwent pancreas head resection as flow diversion surgery. The follow-up periods ranged from 1 to 345 months and from 1 to 271 months (average, 100.2 and 94.1) in patients with type I and type IV-A cysts, respectively. Regarding surgical treatment outcome, postoperative progress was good in 130 (90.3%) of the 144 patients. Fourteen patients required hospitalization for long-term postoperative complications such as cholangitis, pancreatitis, intrahepatic calculi, pancreatic calculus, and carcinogenesis during postoperative follow-up. Of these, 2 patients who underwent surgery for type IV-A cysts died because of secondary biliary cirrhosis with liver failure and advanced intrahepatic cholangiocarcinoma, respectively.The present study shows that flow diversion surgery for congenital choledochal cysts with PBM significantly reduces the risk of subsequent development of malignancy in the biliary tract, and it is vital to choose the appropriate operative procedure to prevent occurrence of these postoperative complications.
- Published
- 2011
7. [The case of tumor escape mechanism by changing their tumor-associated antigens]
- Author
-
Ryuji, Suzuki, Yoshito, Kotera, Nobuhiro, Takeshita, Norimasa, Matsushita, Ryuji, Okuyama, Atsushi, Aruga, and Masakazu, Yamamoto
- Subjects
Antigens, Neoplasm ,Humans ,Female ,Gallbladder Neoplasms ,Tumor Escape ,Dendritic Cells ,Middle Aged ,Cancer Vaccines - Abstract
A 53-year-old woman presented with a diagnosis of advanced gallbladder cancer at our hospital. She was evaluated with CT scan and given a diagnosis of Stage IVb due to the multiple lymph nodes metastases and significant invasion to the artery. However, we underwent simple cholecystectomy followed by immunotherapy that was the hope of herself and her family. The serum level of DUPAN-2 was gradually elevated to 6,800 U/mL, and the metastases to the liver were detected. After we started the dendritic cell vaccine pulsed with autologous tumor-lysate with S-1, DUPAN-2 decreased to 980 U/ mL. The CT scan showed complete response (CR) in the liver metastases and partial response (PR) in the lymph node metastases. However, the serum level of CEA elevated since the MUC-1 peptide was used instead of autologous tumor- lysate, even DUPAN-2 did not. The liver metastases were in control, but the lymph nodes metastases had progressed. She died of the progressed lesion later in approximately one year from the operation. This case demonstrated a possibility of the tumor escape mechanism by changing their tumor-associated antigens.
- Published
- 2009
8. Should the extrahepatic bile duct be resected or preserved in R0 radical surgery for advanced gallbladder carcinoma? Results of a Japanese Society of Biliary Surgery Survey: a multicenter study
- Author
-
Tatsuya Yoshikawa, Ryouta Higuchi, Yoshihito Kodera, Takehiro Ota, Ken Takasaki, Masakazu Yamamoto, Nobuhiro Takeshita, Tatsuo Araida, and Mie Hamano
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,digestive system ,Gastroenterology ,Surgical oncology ,Bile Ducts, Extrahepatic ,Internal medicine ,Surveys and Questionnaires ,Carcinoma ,Medicine ,Humans ,Cholecystectomy ,Radical surgery ,Digestive System Surgical Procedures ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Bile duct ,Gallbladder ,General Medicine ,Middle Aged ,medicine.disease ,medicine.anatomical_structure ,Multicenter study ,Health Care Surveys ,Surgery ,Female ,Gallbladder Neoplasms ,Gallbladder Neoplasm ,business - Abstract
We assessed the significance of an extra bile duct resection by comparing the survival of patients with advanced gallbladder carcinoma who had resected bile ducts with those who had preserved bile ducts. A radical cholecystectomy that includes extra bile duct resections has been performed without any clear evidence of whether an extra bile duct resection is preventive or curative.We conducted a questionnaire survey among clinicians who belonged to the 114 member institutions of the Japanese Society of Biliary Surgery. The questionnaires included questions on the preoperative diagnosis, complications, treatment, and surgical treatment, resection procedures, surgical results, pathological and histological findings, mode and site of recurrence, and the need for additional postoperative treatment. A total of 4243 patients who had gallbladder carcinoma and were treated from January 1, 1994 to December 31, 2003 were identified. The 838 R0 patients with pT2, pT3, and pT4 advanced carcinoma of the gallbladder for which there was no cancer invasion to the hepatoduodenal ligament or cystic duct in the final analysis.The 5-year cumulative survival, postoperative complications, postoperative lymph node metastasis, and local recurrence along the hepatoduodenal ligament were not substantially different between the resected bile duct and the preserved bile duct groups.Our retrospective questionnaire survey showed that an extrahepatic bile duct resection had no preventive value in some patients with advanced gallbladder carcinoma in comparison to similar patients who had no such bile duct resection. An extrahepatic bile duct resection may therefore be unnecessary in advanced gallbladder carcinoma without a direct infiltration of the hepatoduodenal ligament and the cystic duct.
- Published
- 2008
9. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells
- Author
-
Qiao Li, Abbey Carr, Mark Nelson, Alfred E. Chang, Jiyun Yu, Joel Whitfield, Nobuhiro Takeshita, Elizabeth J. Donald, and Amelia C. Grover
- Subjects
CD3 Complex ,T cell ,Fibrosarcoma ,T-Lymphocytes ,Immunology ,Antigens, CD19 ,CD40 Ligand ,Antigen-Presenting Cells ,Lymphocyte Activation ,Immunotherapy, Adoptive ,Interleukin 21 ,Interferon-gamma ,Mice ,Cell Line, Tumor ,medicine ,Immunology and Allergy ,Cytotoxic T cell ,Animals ,IL-2 receptor ,CD40 Antigens ,Antigen-presenting cell ,Mice, Knockout ,B-Lymphocytes ,CD40 ,biology ,Antibodies, Monoclonal ,hemic and immune systems ,Dendritic Cells ,Natural killer T cell ,Interleukin-12 ,CD11c Antigen ,Mice, Inbred C57BL ,medicine.anatomical_structure ,biology.protein ,Interleukin 12 ,Cancer research ,Female ,Interleukin-4 ,Lymph Nodes ,Neoplasm Transplantation - Abstract
To date, molecular targets chosen for Ab activation to generate antitumor effector cells have been confined on T cells, such as TCR/CD3, CD28, CD137 (4-1BB), CD134 (OX40), and inducible costimulator. In this report we investigated the immune function of murine tumor-draining lymph node (TDLN) cells after simultaneous Ab targeting of CD3 on T cells and CD40 on APCs. Anti-CD3 plus anti-CD40-activated TDLN cells secreted significantly higher amounts of IFN-γ, but less IL-10, compared with anti-CD3-activated cells. In adoptive immunotherapy, ligation of CD3 and CD40 resulted in the generation of more potent effector cells in mediating tumor regression. Freshly harvested TDLN cells were composed of ∼60% CD3+ T cells, 30–35% CD19+ B cells, 5% CD11c+ dendritic cells (DC), and few CD14+ or NK cells (each
- Published
- 2005
10. Antitumor reactivity of lymph node cells primed in vivo with dendritic cell-based vaccines
- Author
-
Koichi Shimizu, Nobuhiro Takeshita, Gabriel A. Eickhoff, Keishi Tanigawa, and Alfred E. Chang
- Subjects
Cancer Research ,T cell ,Fibrosarcoma ,Immunology ,Cancer Vaccines ,Immunophenotyping ,Interferon-gamma ,Mice ,Adjuvants, Immunologic ,Antigens, Neoplasm ,medicine ,Lymph node stromal cell ,Tumor Cells, Cultured ,Immunology and Allergy ,Animals ,Antigen-presenting cell ,Interleukin 3 ,Pharmacology ,CD40 ,biology ,Follicular dendritic cells ,Dendritic cell ,Dendritic Cells ,Adoptive Transfer ,Mice, Inbred C57BL ,Disease Models, Animal ,medicine.anatomical_structure ,Hemocyanins ,biology.protein ,Cancer research ,Interleukin 12 ,Female ,Immunotherapy ,Lymph Nodes ,Haptens - Abstract
Tumor lysate-pulsed dendritic cells were used to generate nodal effector T cells in the murine MCA 205 tumor model. Dendritic cells were derived from bone marrow and cultured in granulocyte-macrophage colony-stimulating factor/interleukin 4 before pulsation with tumor lysate. Multiple subcutaneous administrations of tumor lysate-pulsed dendritic cells (TP-DCs) resulted in an approximately eightfold hypertrophy of the vaccine draining nodes, with an increased influx of dendritic (CD11c+/CD80+) cells and B (B220+) cells. The vaccine-primed lymph node (VPLN) cells were secondarily activated with anti-CD3/interleukin 2 and exhibited specific interferon-gamma release to tumor antigen. The adoptive transfer of TP-DC VPLN cells resulted in regression of established 3-day pulmonary metastases. The antitumor reactivity of TP-DC VPLN cells was comparable to anti-CD3/interleukin 2 activated tumor-draining lymph node cells. However, the admixture of keyhole limpet hemocyanin (KLH) with tumor lysate during pulsation of dendritic cells significantly enhanced the induction of tumor-reactive VPLN cells. Tumor lysate-pulsed dendritic cells can be used as a strategy to generate effector T cells for adoptive immunotherapy.
- Published
- 2002
11. Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer
- Author
-
Nobuhiro Takeshita, Masakazu Yamamoto, Atsushi Aruga, Ryuji Okuyama, Kazuyoshi Takeda, Takehiro Ohta, Norimasa Matsushita, and Yoshihito Kotera
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Phases of clinical research ,Cancer Vaccines ,General Biochemistry, Genetics and Molecular Biology ,Disease-Free Survival ,Epitopes ,Immune system ,Monitoring, Immunologic ,Internal medicine ,Injection site reaction ,medicine ,Cancer vaccine ,Humans ,Adverse effect ,Aged ,Neoplasm Staging ,Medicine(all) ,Peptide vaccine ,Chemotherapy ,Biochemistry, Genetics and Molecular Biology(all) ,business.industry ,Research ,Vaccination ,Immunity ,General Medicine ,Immunotherapy ,Middle Aged ,medicine.disease ,Neoplasm Proteins ,Clinical trial ,Kinetics ,Biliary Tract Neoplasms ,Treatment Outcome ,Immunology ,Vaccines, Subunit ,Biliary tract cancer ,Female ,business ,T-Lymphocytes, Cytotoxic - Abstract
The prognosis of patients with advanced biliary tract cancer (BTC) is extremely poor and only a few standard treatments are available for this condition. We performed a phase I trial to investigate the safety, immune response and anti-tumor effect of vaccination with three peptides derived from cancer-testis antigens. This study was conducted as a phase I trial. Nine patients with advanced BTC who had unresectable tumors and were refractory to standard chemotherapy were enrolled. Three HLA-A*2402 restricted epitope peptides-cell division cycle associated 1 (CDCA1), cadherin 3 (CDH3) and kinesin family member 20A (KIF20A)-were administered subcutaneously, and the adverse events and immune response were assessed. The clinical effects observed were the tumor response, progression-free survival (PFS) and overall survival (OS). The three-peptide vaccination was well-tolerated up to a dose of 3 mg per peptide (9 mg total). No grade 3 or 4 adverse events were observed after vaccination. Peptide-specific T cell immune responses were observed in all patients and stable disease was observed in 5 of 9 patients. The median PFS and OS were 3.4 and 9.7 months. The Grade 2 injection site reaction and continuous vaccination after PD judgment appeared to be prognostic of OS. Multiple-peptide vaccination was well tolerated and induced peptide-specific T-cell responses. This study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN- CTR000003229 ).
- Published
- 2014
12. Tumor-specific responses in lymph nodes draining murine sarcomas are concentrated in cells expressing P-selectin binding sites
- Author
-
Ronald A. Craig, Nobuhiro Takeshita, Lloyd M. Stoolman, Keishi Tanigawa, Katie Phillips, Alfred E. Chang, and Randall N. Knibbs
- Subjects
Adoptive cell transfer ,Lung Neoplasms ,Ovalbumin ,Fibrosarcoma ,Receptors, Antigen, T-Cell, alpha-beta ,Recombinant Fusion Proteins ,Sialoglycoproteins ,Immunology ,Mice, Transgenic ,Biology ,Lymphocyte Activation ,Immunophenotyping ,Chimera (genetics) ,Interferon-gamma ,Mice ,Antigens, CD ,T-Lymphocyte Subsets ,medicine ,Tumor Cells, Cultured ,Immunology and Allergy ,Animals ,Lymph node ,Cells, Cultured ,Inflammation ,Lymphokines ,Membrane Glycoproteins ,Effector ,Immunomagnetic Separation ,Lymphoblast ,Cell Differentiation ,Molecular biology ,Adoptive Transfer ,Receptors, Fibroblast Growth Factor ,In vitro ,Mice, Inbred C57BL ,P-Selectin ,medicine.anatomical_structure ,Immunoglobulin M ,Female ,Immunization ,Lymph ,Lymph Nodes ,E-Selectin ,CD8 - Abstract
Tumor-draining lymph node (TDLN) cells develop substantial antitumor activity after activation on immobilized αCD3 and culture in low-dose IL-2. This study found that the minor subset of TDLN T cells expressing binding sites for the adhesion receptor P-selectin (Plighigh T cells) produced T lymphoblasts with the most tumor-specific IFN-γ synthesis in vitro and antitumor activity following adoptive transfer in vivo. The Plighigh T cells constituted 30-fold more active than cultured TDLN cells depleted of the Plighigh fraction before expansion (Pliglow cells). Tumor-specific IFN-γ synthesis in vitro paralleled the antitumor activities of the cultured fractions in vivo, implying that increased Tc1 and Th1 effector functions contributed to the tumor suppression. Neither nonspecific interaction with the P-selectin chimera used for sorting nor endogenous costimulatory activity in the Plighigh fraction accounted for the marked increase in antitumor activities after culture. The cultured Plighigh fraction contained a variety of potential effector cells; however, the CD8 and CD4 subsets of αβ T cells accounted for 95–97% of its antitumor activity. The authors propose that P-selectin sorting increased antitumor activities by concentrating Tc1 and Th1 pre-effector/effector cells before culture.
- Published
- 2001
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.